Jin Kyeong Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jin Kyeong Lee has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Byeongkwon Kim
Department of Bioscience and Biotechnology
4 shared publications- Yangmee Kim
Konkuk University
4 shared publications Chae Yeong Lee
Department of Bioscience and Biotechnology
2 shared publicationsDasom Song
Department of Chemistry
2 shared publicationsEunha Hwang
Biopharmaceutical Research Center
2 shared publicationsHyeju Lee
Department of Bioscience and Biotechnology
2 shared publications
Latest Publications
- 19 September 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (19) , 20283-20303
Therapeutic Potential of Novel Antimicrobial Peptide Pap12-6-10: Mechanisms of Antibacterial and Anti-inflammatory Action Against Gram-Negative Sepsis
To develop novel antibiotics, we engineered 12-mer peptides derived from the N-terminus of papiliocin. Pap12-6-10 emerged as a potent antibacterial agent against multidrug-resistant Gram-negative bacteria, demonstrating a low propensity for resistance development. Pap12-6-10 exerts its antibacterial activity by permeabilizing bacterial membranes through binding to lipopolysaccharide (LPS), inducing oxidative stress that leads to cell death. Pap12-6-10 modulates LPS-induced inflammatory responses by selectively targeting the TLR4 signaling pathways. Structural analysis using NMR, surface plasmon resonance, docking, and molecular dynamics simulations suggested that Pap12-6-10 binds to the hydrophobic pocket of MD-2, thereby preventing the LPS-induced dimerization of the TLR4/MD-2 complex, which is essential for inflammatory signaling during sepsis. In the Escherichia coli K1 and carbapenem-resistant Acinetobacter baumannii-induced sepsis mouse model Pap12-6-10 protected organ damage from septic shock and displayed significant therapeutic effects while maintaining low cytotoxicity. This study highlights its potential as a valuable candidate for treating Gram-negative infections.
- 19 September 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (19) , 20283-20303
Therapeutic Potential of Novel Antimicrobial Peptide Pap12-6-10: Mechanisms of Antibacterial and Anti-inflammatory Action Against Gram-Negative Sepsis
To develop novel antibiotics, we engineered 12-mer peptides derived from the N-terminus of papiliocin. Pap12-6-10 emerged as a potent antibacterial agent against multidrug-resistant Gram-negative bacteria, demonstrating a low propensity for resistance development. Pap12-6-10 exerts its antibacterial activity by permeabilizing bacterial membranes through binding to lipopolysaccharide (LPS), inducing oxidative stress that leads to cell death. Pap12-6-10 modulates LPS-induced inflammatory responses by selectively targeting the TLR4 signaling pathways. Structural analysis using NMR, surface plasmon resonance, docking, and molecular dynamics simulations suggested that Pap12-6-10 binds to the hydrophobic pocket of MD-2, thereby preventing the LPS-induced dimerization of the TLR4/MD-2 complex, which is essential for inflammatory signaling during sepsis. In the Escherichia coli K1 and carbapenem-resistant Acinetobacter baumannii-induced sepsis mouse model Pap12-6-10 protected organ damage from septic shock and displayed significant therapeutic effects while maintaining low cytotoxicity. This study highlights its potential as a valuable candidate for treating Gram-negative infections.
- 4 September 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (18) , 19303-19330
A Novel Peptide Antibiotic Targeting Gram-Negative Infections Designed from Mycobacterium tuberculosis Adenylate Kinase
We explored the lipopolysaccharide-binding properties of adenylate kinase from Mycobacterium tuberculosis (MtAdk) to facilitate the design of novel peptide antibiotics. Notably, we de novo designed 11-mer peptides derived from the AMP-binding domain (Lys44 to Asp54) of MtAdk. Among 71 designed peptides, DD-S067 was the most effective, especially against carbapenem-resistant Acinetobacter baumannii (CRAB), with minimal development of drug resistance. DD-S067 exhibited multiple antibacterial mechanisms, including disrupting both the outer and inner bacterial membranes, and inducing reactive oxygen species that trigger lipid peroxidation. Transcriptome analysis revealed that DD-S067 disrupted key cellular pathways in CRAB by inhibiting the electron transport chain and triggering oxidative stress responses, ultimately suppressing CRAB virulence mechanisms. Furthermore, DD-S067 exhibited significant protective effects in a CRAB-induced septic shock mouse model, highlighting its potential as a novel peptide antibiotic for treating Gram-negative infections. These findings pave the way for innovative strategies in developing protein-based antibiotics.
- 4 September 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (18) , 19303-19330
A Novel Peptide Antibiotic Targeting Gram-Negative Infections Designed from Mycobacterium tuberculosis Adenylate Kinase
We explored the lipopolysaccharide-binding properties of adenylate kinase from Mycobacterium tuberculosis (MtAdk) to facilitate the design of novel peptide antibiotics. Notably, we de novo designed 11-mer peptides derived from the AMP-binding domain (Lys44 to Asp54) of MtAdk. Among 71 designed peptides, DD-S067 was the most effective, especially against carbapenem-resistant Acinetobacter baumannii (CRAB), with minimal development of drug resistance. DD-S067 exhibited multiple antibacterial mechanisms, including disrupting both the outer and inner bacterial membranes, and inducing reactive oxygen species that trigger lipid peroxidation. Transcriptome analysis revealed that DD-S067 disrupted key cellular pathways in CRAB by inhibiting the electron transport chain and triggering oxidative stress responses, ultimately suppressing CRAB virulence mechanisms. Furthermore, DD-S067 exhibited significant protective effects in a CRAB-induced septic shock mouse model, highlighting its potential as a novel peptide antibiotic for treating Gram-negative infections. These findings pave the way for innovative strategies in developing protein-based antibiotics.
- 30 October 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (21) , 19791-19812
Antibacterial, Antibiofilm, and Anti-inflammatory Effects of a Novel Thrombin-Derived Peptide in Sepsis Models: Insights into Underlying Mechanisms
We developed two short helical antimicrobial peptides, HVF18-a3 and its d-enantiomer, HVF18-a3-d, derived from the thrombin C-terminal peptide HVF18. These peptides exhibit potent antimicrobial activity against various bacteria by compromising both the outer and inner membranes, with low hemolytic activity. They are stable in the presence of physiological salts and human serum, exhibiting a low potential for developing drug resistance and excellent antibiofilm activity against Gram-negative bacteria. HVF18-a3-d also neutralized lipopolysaccharide (LPS) through direct binding interactions and suppressed the production of inflammatory cytokines through the inflammatory signaling pathway mediated by Toll-like receptor 4 in RAW264.7 cells stimulated with LPS. Both pre- and post-treatment with HVF18-a3-d significantly protected mice against fatal septic shock induced by carbapenem resistant Acinetobacter baumannii. These findings suggest HVF18-a3 and HVF18-a3-d are promising candidates for developing antibiotics against Gram-negative sepsis.
- 30 October 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (21) , 19791-19812
Antibacterial, Antibiofilm, and Anti-inflammatory Effects of a Novel Thrombin-Derived Peptide in Sepsis Models: Insights into Underlying Mechanisms
We developed two short helical antimicrobial peptides, HVF18-a3 and its d-enantiomer, HVF18-a3-d, derived from the thrombin C-terminal peptide HVF18. These peptides exhibit potent antimicrobial activity against various bacteria by compromising both the outer and inner membranes, with low hemolytic activity. They are stable in the presence of physiological salts and human serum, exhibiting a low potential for developing drug resistance and excellent antibiofilm activity against Gram-negative bacteria. HVF18-a3-d also neutralized lipopolysaccharide (LPS) through direct binding interactions and suppressed the production of inflammatory cytokines through the inflammatory signaling pathway mediated by Toll-like receptor 4 in RAW264.7 cells stimulated with LPS. Both pre- and post-treatment with HVF18-a3-d significantly protected mice against fatal septic shock induced by carbapenem resistant Acinetobacter baumannii. These findings suggest HVF18-a3 and HVF18-a3-d are promising candidates for developing antibiotics against Gram-negative sepsis.
- 29 August 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (17) , 15148-15167
Impact of Conjugation of the Reactive Oxygen Species (ROS)-Generating Catalytic Moiety with Membrane-Active Antimicrobial Peptoids: Promoting Multitarget Mechanism and Enhancing Selectivity
Antimicrobial peptides (AMPs) represent promising therapeutic modalities against multidrug-resistant bacterial infections. As a mimic of natural AMPs, peptidomimetic oligomers like peptoids (i.e., oligo-N-substituted glycines) have been utilized for antimicrobials with resistance against proteolytic degradation. Here, we explore the conjugation of catalytic metal-binding motifs─the amino terminal Cu(II) and Ni(II) binding (ATCUN) motif─with cationic amphipathic antimicrobial peptoids to enhance their efficacy. Upon complexation with Cu(II) or Ni(II), the conjugates catalyzed hydroxyl radical generation, and 22 and 22-Cu exhibited over 10-fold improved selectivity compared to the parent peptoid, likely due to reduced hydrophobicity. Cu-ATCUN-peptoids caused bacterial membrane disruption, aggregation of intracellular biomolecules, DNA oxidation, and lipid peroxidation, promoting multiple killing mechanisms. In a mouse sepsis model, 22 demonstrated antimicrobial and anti-inflammatory efficacy with low toxicity. This study suggests a strategy to improve the potency of membrane-acting antimicrobial peptoids by incorporating ROS-generating motifs, thereby adding oxidative damage as a killing mechanism.
- 29 August 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (17) , 15148-15167
Impact of Conjugation of the Reactive Oxygen Species (ROS)-Generating Catalytic Moiety with Membrane-Active Antimicrobial Peptoids: Promoting Multitarget Mechanism and Enhancing Selectivity
Antimicrobial peptides (AMPs) represent promising therapeutic modalities against multidrug-resistant bacterial infections. As a mimic of natural AMPs, peptidomimetic oligomers like peptoids (i.e., oligo-N-substituted glycines) have been utilized for antimicrobials with resistance against proteolytic degradation. Here, we explore the conjugation of catalytic metal-binding motifs─the amino terminal Cu(II) and Ni(II) binding (ATCUN) motif─with cationic amphipathic antimicrobial peptoids to enhance their efficacy. Upon complexation with Cu(II) or Ni(II), the conjugates catalyzed hydroxyl radical generation, and 22 and 22-Cu exhibited over 10-fold improved selectivity compared to the parent peptoid, likely due to reduced hydrophobicity. Cu-ATCUN-peptoids caused bacterial membrane disruption, aggregation of intracellular biomolecules, DNA oxidation, and lipid peroxidation, promoting multiple killing mechanisms. In a mouse sepsis model, 22 demonstrated antimicrobial and anti-inflammatory efficacy with low toxicity. This study suggests a strategy to improve the potency of membrane-acting antimicrobial peptoids by incorporating ROS-generating motifs, thereby adding oxidative damage as a killing mechanism.